Lataa...
Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia
The use of small molecules became one key cornerstone of targeted anti-cancer therapy. Among them, tyrosine kinase inhibitors (TKIs) are especially important, as they were the first molecules to proof the concept of targeted anti-cancer treatment. Since 2001, TKIs can be successfully used to treat c...
Tallennettuna:
| Julkaisussa: | Front Pharmacol |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8273252/ https://ncbi.nlm.nih.gov/pubmed/34262462 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2021.696960 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|